engineering human tissue implants
Advanced Therapies Congress London 2022
2.5m patients in the US alone suffer from severe CVI due to reflux
$30b annual wound care costs in the US, on average $30k per patient and year
40% more work-days missed than healthy people
20% - 40% 1-year ulcer recurrence - continuous treatment needed
No effective treatment options to date
ClexBio’s solution: Tissue-engineered human vein grafts
Biocompatible: Final product consisting of extracellular matrix (ECM) produced by healthy human cells
Functional: Grafts have functional bi-cuspal valves and optimal mechanical properties mimicking real veins
Allogeneic: Cells are removed, resulting in non-immunogenic graft for transplant to any CVI patient
Scalable: Manufacturing process can be parallelized and scaled to meet global demand
Permanent: Eliminate reflux and permanently treat CVI
VivoSet is a technology that utilizes healthy human cells to grow tissues composed of extracellular matrix . The uniqueness of VivoSet is the ability to grow large tissues rapidly in any chosen geometry, e.g. veins and other conduits.
VivoSet's USPs:
1) Recreate complex tissue geometries
2) Macroscopic dimensions (~cm, not limited by diffusion barrier of 100 um)
3) Fast tissue formation
4) Mechanically strong
5) Scalability of formulation
We are currently looking for globally leading CROs for preclinical in vivo testing, manufacturing partners, and enthusiastic investors that want to be part of our mission. Please reach out to learn more about ClexBio.
